John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

As obesity clinical trials evolve, there is a growing emphasis on how decentralisation and new technologies can play a role.

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

Three cities in Hawaii, Minnesota, and Texas report the highest usage of injectable weight loss medications. Meanwhile, ...

The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...

Americans’ waistlines have grown relentlessly for decades: a costly, debilitating and deadly trend that prompted observers to wonder if and when they would finally stop expanding. Well, the federal go ...

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...

Popular weight-loss medications including Ozempic and Wegovy contain a drug that seems to decrease cravings for food and ...